Busulfan pharmacokinetics following intravenous and oral dosing regimens in children receiving high-dose myeloablative chemotherapy for high-risk neuroblastoma as part of the HR-NBL-1/SIOPEN trial

European Journal of Cancer

Volumn 48, Issue 16, 2012, Pages 3063-3072

  Veal, G J ^a,f   Nguyen, L ^b,f   Paci, A ^c,f   Riggi, M ^b,f   Amiel, M ^b,f   Valteau Couanet, D ^c,f   Brock, P ^d,f   Ladenstein, R ^e,f   Vassal, G ^c,f  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b INSTITUT DE RECHERCHE PIERRE FABRE   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^e ST ANNA CHILDREN S HOSPITAL   (Austria)

^f SIOPEN Pharmacology Group   (Austria)

Author keywords

Busulphan; Neuroblastoma; Paediatrics; Pharmacokinetics

Indexed keywords

BUSULFAN; MELPHALAN;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CHILD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG FATALITY; DRUG MEGADOSE; FEMALE; GAS CHROMATOGRAPHY; HIGH RISK PATIENT; HUMAN; INFANT; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; NEUROBLASTOMA; PLASMA CONCENTRATION-TIME CURVE; PRESCHOOL CHILD; PRIORITY JOURNAL; RESPIRATORY DISTRESS; SCHOOL CHILD;

ADMINISTRATION, ORAL; ADOLESCENT; AREA UNDER CURVE; BUSULFAN; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; DRUG-INDUCED LIVER INJURY; EUROPE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; INFANT; INJECTIONS, INTRAVENOUS; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; MYELOABLATIVE AGONISTS; NEUROBLASTOMA; RISK ASSESSMENT; RISK FACTORS;

EID: 84867578023     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.05.020     Document Type: Article

References (33)

1. R. Ladenstein, U. Pötschger, and O. Hartman 28 years of high-dose therapy and SCT for neuroblastoma in Europe: lessons from more than 4000 procedures Bone Marrow Transplant 41 2008 S118 27
2. G. Vassal, S. Koscielny, and D. Challine Busulfan disposition and hepatic veno-occlusive disease in children undergoing bone marrow transplantation Cancer Chemother Pharmacol 37 1996 247 253
3. M. Hassan, A. Fasth, and B. Gerritsen Busulphan kinetics and limited sampling model in children with leukemia and inherited disorders Bone Marrow Transplant 18 1996 843 850
4. B. Bostrom, K. Enockson, and A. Johnson Plasma pharmacokinetics of high-dose oral busulfan in children and adults undergoing bone marrow transplantation Pediatr Transplant 7 2003 12 28
5. S.P. Dix, J.R. Wingard, and R.E. Mullins Association of busulfan area under the curve with veno-occlusive disease following BMT Bone Marrow Transplant 17 1996 225 230
6. J.T. Slattery, R.A. Clift, and C.D. Buckner Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation Blood 89 1997 3055 3060
7. N. Bleyzac, G. Souillet, and P. Magron Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens Bone Marrow Transplant 28 2001 743 751
8. A.M. Bolinger, A.B. Zangwill, and J.T. Slattery Target dose adjustment of busulfan in pediatric patients undergoing bone marrow transplantation Bone marrow transplant 28 2001 1013 1018
9. N. Krivoy, E. Hoffer, and A. Tabak Therapeutic monitoring of busulfan in pediatric bone marrow transplantation Pediatr Hematol Oncol 19 2002 31 37
10. H. Tran, D. Petropoulos, and L. Worth Pharmacokinetics and individualized dose adjustment of intravenous busulfan in children with advanced hematologic malignancies undergoing allogeneic stem cell transplantation Biol Blood Marrow Transplant 10 2004 805 812
11. L. Nguyen, F. Leger, and S. Lennon Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study Cancer Chemother Pharmacol 57 2006 191 198
12. F. Leger, L. Nguyen, and C. Puozzo Exposure equivalence between IV (0.8 mg/kg) and oral (1 mg/kg) busulfan in adult patients Eur J Clin Pharmacol 65 2009 903 911
13. L. Nguyen, D. Fuller, and S. Lennon IV busulfan in paediatrics: a novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients Bone Marrow Transplant 33 2004 979 987
14. G. Vassal, G. Michel, and H. Espérou Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring Cancer Chemother Pharmacol 61 2008 113 123
15. G. Michel, D. Valteau-Couanet, and J.-C. Gentet Weight-based strategy of dose administration in children using intravenous busulfan: clinical and pharmacokinetic results Pediatr Blood Cancer 58 2011 90 97
16. K.K. Matthay, C.P. Reynolds, and R.C. Seeger Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a Children's Oncology Group study J Clin Oncol 27 2009 1007 1013
17. R. Ladenstein, D. Valteau-Couanet, and P. Brock Randomized trial of prophylactic granulocyte colony-stimulating factor during rapid COJEC induction in pediatric patients with high-risk neuroblastoma: the European HR-NBL-1/SIOPEN study J Clin Oncol 28 2010 3516 3524
18. R.L. Ladenstein, U. Poetschger, and R. Luksch Busulphan-melphalan as a myeloablative therapy (MAT) for high-risk neuroblastoma: results from the HR-NBL1/SIOPEN trial J Clin Oncol 29 Suppl. 2011 2
19. S.I. Bearman, F.R. Appelbaum, and C.D. Buckner Regimen-related toxicity in patients undergoing bone marrow transplantation J Clin Oncol 6 1988 1562 1568
20. G. Vassal, M. Re, and A. Gouyette Gas chromatographic-mass spectrometric assay for busulfan in biological fluids using a deuterated internal standard J Chromatogr 428 1988 357 361
21. B. Schiltmeyer, T. Klingebiel, and M. Schwab Population pharmacokinetics of oral busulfan in children Cancer Chemother Pharmacol 52 2003 209 216
22. M. Hassan, G. Oberg, and A.N. Bekassy Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacology Cancer Chemother Pharmacol 28 1991 130 134
23. M. Hassan, H. Ehrsson, and P. Ljungman Aspects concerning busulfan pharmacokinetics and bioavailability Leuk Lymphoma 22 1996 395 407
24. J.P. Gibbs, C.A. Liacouras, and R.N. Baldassano Up-regulation of glutathione S-transferase activity in enterocytes of young children Drug Metab Dispos 27 1999 1466 1469
25. M. Hassan, P. Ljungman, and P. Bolme Busulfan bioavailability Blood 84 1994 2144 2150
26. M.N. Trame, M. Bergstrand, and M.O. Karlsson Population pharmacokinetics of busulfan in children: increased evidence for body surface area and allometric body weight dosing of busulfan in children Clin Cancer Res 17 2011 6867 6877
27. L. Nguyen, A. Paci, and G. Vassal Comparison of individualized intravenous busulfan dosing in pediatric patients undergoing bone marrow transplantation - Letter to the Editor Clin Cancer Res 18 2012 2715 2716
28. Y.S. Chae, S.K. Sohn, and J.G. Kim New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2 Bone Marrow Transplant 40 2007 541 547
29. J. Bouligand, and I. Boland Valteau-Couanet, et al. In children and adolescents, the pharmacodynamics of high-dose busulfan is dependent on the second alkylating agent used in the combined regimen (melphalan or thiotepa) Bone Marrow Transplant 32 2003 979 986
30. L.B. Grochow, W. Krivit, and C.B. Whitley Busulfan disposition in children Blood 75 1990 1723 1727
31. J.-H. Lee, S.-J. Choi, and J.-H. Lee Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan + cyclophosphamide for allogeneic bone marrow transplantation Ann Hematol 84 2005 321 330
32. I.H. Bartelink, R.G.M. Bredius, and S.V. Belitser Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematologic stem cell transplantation Biol Blood Marrow Transplant 15 2009 231 241
33. D. Wall, K. Wah Chan, and M.L. Nieder Safety, efficacy and pharmacokinetics of intravenous busulfan in children undergoing allogeneic hematopoietic stem cell transplantation Pediatr Blood Cancer 54 2010 291 298